Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 11,368 shares, a growth of 164.4% from the December 15th total of 4,299 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 49,488 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 49,488 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.3% of the shares of the stock are short sold.

Institutional Investors Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP bought a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix at the end of the most recent quarter. 11.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Pulmatrix Stock Up 4.9%

NASDAQ PULM opened at $2.49 on Friday. The stock’s 50-day moving average is $3.60 and its 200-day moving average is $4.66. Pulmatrix has a one year low of $2.15 and a one year high of $10.40.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).